{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:30:02Z","timestamp":1794051002460,"version":"4.8.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ijantimicag.2023.107016","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T21:18:43Z","timestamp":1698355123000},"page":"107016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in HIV late presenters"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8059-7171","authenticated-orcid":false,"given":"Diana","family":"Corona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-7135","authenticated-orcid":false,"given":"Ignacio","family":"P\u00e9rez-Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0217-5122","authenticated-orcid":false,"given":"\u00c1ngela","family":"Guti\u00e9rrez Liarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-5394","authenticated-orcid":false,"given":"Marta","family":"Montero-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Remedios","family":"Alem\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Ruiz-Seco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"P\u00e9rez Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melchor","family":"Riera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Jarrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.107016_bib0001","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile","volume":"60","author":"Tsiang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0002","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380\u20131489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0003","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0004","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0005","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0006","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services 2022, https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv; 2022 [accessed 10.19.23]."},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0007","series-title":"Documento de consenso de Gesida\/Plan nacional sobre el sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana","year":"2023"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0008","doi-asserted-by":"crossref","first-page":"946","DOI":"10.7326\/0003-4819-126-12-199706150-00003","article-title":"Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection","volume":"126","author":"Mellors","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0009","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0010","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(11)60983-5","article-title":"Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial","volume":"378","author":"Cohen","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0011","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0012","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001510","article-title":"Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)","volume":"10","author":"Mocroft","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0014","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1093\/jac\/dkab168","article-title":"Group the RET. Redefining therapeutic success in HIV patients: an expert view","volume":"76","author":"Antela","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0015","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.eimc.2011.06.002","article-title":"[The Cohort of the Spanish HIV Research Network (CoRIS) and its associated biobank; organizational issues, main findings and losses to follow-up]","volume":"29","author":"Sobrino-Vegas","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0016","doi-asserted-by":"crossref","first-page":"ofac018","DOI":"10.1093\/ofid\/ofac018","article-title":"Advanced HIV infection in treatment-na\u00efve individuals: effectiveness and persistence of recommended 3-drug regimens","volume":"9","author":"Mounzer","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.107016_bib0017","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/hiv.13467","article-title":"Immune response to ART initiation in advance HIV infection","volume":"24","author":"Mounzer","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0018","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40121-022-00734-5","article-title":"Comparison of virological efficacy of DTG\/ABC\/3TG and B\/F\/TAF regimens and discontinuation patterns in persons living with advanced HIV in the era of rapid ART: a retrospective multicenter cohort study","volume":"12","author":"Chun-Yuan","year":"2023","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0019","unstructured":"NEAT ID Foundation. The Late Presenter Treatment Optimisation Study (LAPTOP). ClinicalTrials.gov identifier: NCT03696160."},{"key":"10.1016\/j.ijantimicag.2023.107016_bib0020","series-title":"Conference on Retroviruses and Opportunistic Infections 2020","article-title":"Patterns of adherence in bictegravir and dolutegravir-based regimens","author":"Sax","year":"2020"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792300290X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485792300290X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:48:35Z","timestamp":1760377715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485792300290X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S092485792300290X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107016","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in HIV late presenters","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.107016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107016"}}